Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

5.030 -0.040 (-0.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo
From Precision BioSciences, Inc.
Via Business Wire
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
Precision BioSciences Appoints Alex Kelly as Chief Financial Officer
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference
From Precision BioSciences Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Enveric Biosciences (NASDAQ:ENVB)... 
Via Benzinga
Precision BioSciences' CD-19 CAR T Therapy Shows Response Rate Of 77% In Lymphoma Trial
Precision BioSciences Inc (NASDAQ: DTIL) announced additional data from its Phase 1/2a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Precision BioSciences to Present Data from its First Generation CD19 Allogeneic CAR T Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 American Society of Clinical Oncology Meeting
From Precision BioSciences, Inc.
Via Business Wire
Recap: Precision BioSciences Q1 Earnings
Shares of Precision BioSciences (NASDAQ:DTIL) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were up 36.54% year over year to ($... 
Via Benzinga
Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Why Precision BioSciences Stock Is Trading Higher Today
Precision BioSciences (NASDAQ: DTIL) shares are trading higher after the company reported its ARCUS platform showed a promising gene editing approach for transthyretin... 
Via Benzinga
Precision BioSciences Shares Move Higher As ARCUS Platform Shows Promising Gene Editing Approach For Transthyretin Amyloidosis
Precision BioSciences Inc (NASDAQ: DTIL) has announced new in vivo data using ARCUS genome editing platform resulting from a preclinical research... 
Via Benzinga
New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Ardelyx, Inc. (NASDAQ:... 
Via Benzinga
Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs
From Precision BioSciences Inc.
Via Business Wire
Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series
From Precision BioSciences Inc.
Via Business Wire
51 Biggest Movers From Yesterday
Gainers UTime Limited (NASDAQ: UTME) shares jumped 875% to close at $39.00 on Tuesday after the company priced its IPO at $4 per share. Romeo Power, Inc. (NYSE: RMO) climbed 59.6... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.